Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer
Authors:
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 37, 312-319
Abstract
No abstract availableKeywords
Funding Information
- NSF (1056997, P30 CA023168)
- Purdue University
- Purdue Research Foundation Research
- Indiana CTSI Core Pilot Award
- Mildred Elizabeth Edmundson Research Grant
- Purdue University Center for Cancer Research Small Grants Program
This publication has 57 references indexed in Scilit:
- Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian CancerClinical Cancer Research, 2012
- Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer ChemotherapeuticsClinical Pharmacokinetics, 2012
- Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumorsJournal of Controlled Release, 2012
- Recent progress in the diagnosis and treatment of ovarian cancerCA: A Cancer Journal for Clinicians, 2011
- Role of Versican, Hyaluronan and CD44 in Ovarian Cancer MetastasisInternational Journal of Molecular Sciences, 2011
- Intraperitoneal Therapy for Peritoneal CancerFuture Oncology, 2010
- Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in RodentsJournal of Pharmaceutical Sciences, 2010
- Intralymphatic Chemotherapy Using a Hyaluronan–Cisplatin ConjugateJournal of Surgical Research, 2008
- In Situ Cross-linkable Hyaluronan Hydrogels Containing Polymeric Nanoparticles for Preventing Postsurgical AdhesionsAnnals of Surgery, 2007
- Hyperproduction of Hyaluronan in Neu-Induced Mammary Tumor Accelerates Angiogenesis through Stromal Cell RecruitmentThe American Journal of Pathology, 2007